[Clinical studies of S-1108 fine granules in pediatrics].
We have evaluated S-1108 fine granules for therapeutic effectiveness in children. The results are summarized as follows. 1. A clinical study was performed with 16 children with infections, including 8 with acute tonsillitis, 3 with acute pharyngitis, 2 with scarlet fever, 1 each with acute bronchitis, pertussis and urinary tract infection. Doses ranging from 8.8 to 10.6 mg/kg body weights were given in 3 divided portions. Durations of treatment ranged from 2 to 15 days. The therapeutic responses were considered "excellent" in 1 and "good" in 13, with an efficacy rate of 87.5%, and the bacteriological eradication rate was 91%. 2. No adverse reactions were observed. In laboratory tests, eosinophilia was observed in one patient. It was concluded the S-1108 was promising drug for the treatment of bacterial infections in children.
Morita
H
H
Department of Pediatrics, Kochi Medical School.
Morisawa
Y
Y
Hamada
F
F
Kurashige
T
T
D000284:Administration, Oral; D002511:Cephalosporins / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D011355:Prodrugs / Q000008:administration & dosage*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D011355:Prodrugs; C076133:S 1108